Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - USFDA Classifies Inspection At Indrad Facility As OAI

 The Company has received a communication from the USFDA classifying the inspection conducted at its Indrad facility in April, 2019 as Official Action Initiated (OAI). The Company already had submitted its initial response to USFDA and commitments given in response to Form 483 observations have been fulfilled. The Company is sending further updates over receiving of this OAI letter. The Company will be engaging with the regulator and is fully committed in resolving this issue at the earliest. The Company does not believe that this inspection classification will have an impact of disruption of supplies or the revenues from operations of this facility. This is for your information and record.
12-08-2019
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of Loss of Share Certificate
09-08-2019
Bigul

Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of Loss of Share Certificate
07-08-2019
Bigul

Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Intimation of issue of duplicate share certificate
26-07-2019
Bigul

Torrent Pharmaceuticals Ltd - 500420 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)

 Torrent Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here
25-07-2019
Bigul

Torrent Pharma sees best day in over 11 months as Q1 profit beats estimates

 Shares of Torrent Pharmaceuticals Ltd rose as much as 6.2 per cent to Rs 1,559, posting their biggest intra-day per cent gain since August 3, 2018.Jun
24-07-2019
Bigul

Torrent Pharmaceuticals Ltd - 500420 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 46TH ANNUAL GENERAL MEETING HELD ON 23RD JULY, 2019 - Declaration of Results of e-voting and poll
23-07-2019
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Change in Directorate

 The Board has at its meeting held today approved the appointment of Shri Jinesh Shah as an Additional Director on the Board of the Company till the next Annual General Meeting and also Whole-time Director, designated as Director (Operations) for a period of 5 years with effect from 01-Aug-19 subject to approval of the shareholders. He is not related to any other Director of the Company. Further, we would like to inform that Shri Shah is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
23-07-2019
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation

 The presentation on unaudited Consolidated Financial Results for the quarter ended 30th June, 2019 to be made to analysts is enclosed for your records.
23-07-2019
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Submission / Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), 2015, ('Listing Regulations')

 The Board has at its meeting held today approved, inter-alia, the following: (a) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter ended on 30th June, 2019. The said financial results are enclosed herewith. (b) Approved the appointment of Shri Jinesh Shah as an Additional Director on the Board of the Company till the next Annual General Meeting and also Whole-time Director, designated as Director (Operations) for a period of 5 years with effect from 01-Aug-19 subject to approval of the shareholders. He is not related to any other Director of the Company. Further, we would like to inform that Shri Shah is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.
23-07-2019
Next Page
Close

Let's Open Free Demat Account